Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs McKesson Corporation (MCK) Price & Performance

Boston Scientific CorporationTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs McKesson Corporation — how do they compare? Boston Scientific Corporation trades at $51 (market cap $71.46B), while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation is the larger of the two by market cap, and McKesson Corporation pays a 0.43% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXMCK
Market Cap
$71.46B$102.58B
Sector
HealthHealth
52-Week High
$108.14$995.69
52-Week Low
$42.63$659.01
Enterprise Value
$83.55B$109.12B
Dividend Yield
0.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

No Aura AI signal available yet.

McKesson Corporation

McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.

Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK